Scholarlink

Background <p>Positron emission tomography with 18F-fluorodeoxyglucose (18F-FDG-PET/CT) is the gold standard for staging and treatment response assessment in patients with malignant lymphoma. However, 18F-FDG-PET/CT uses significant dose of ionizing radiation, which is a potential risk of secondary malignancies. Whole-body diffusion-weighted MRI (WB-DW-MRI) is a promising, radiation-free alternative for staging and assessment of response in patients with lymphoma. However, till now, WB-MRI is not routinely used in patients with lymphoma. The aim of this study was to assess the role of whole-body diffusion-weighted MR sequence in management of lymphoma, compared to conventional FDG-PET CT, as well as to ascertain whether WB-DW-MRI is a good alternative to FDG PET/ CT for the diagnosis of lymphoma and subsequent treatment evaluation. The study was conducted on 20 patients (17males, 3 females) who presented with histopathologically proved lymphoma for initial evaluation or for follow-up. All patients were subjected to full history taking, clinical examination report review, as well as other imaging modalities whenever available, followed by FDG PET/CT examination. Patients were then further reevaluated by whole-body diffusion-weighted imaging to determine whether they were comparable in the diagnostic and or treatment response assessment.</p> Results <p>Thirty-six of our patients had non-Hodgkin’s lymphoma (NHL), while 4 had Hodgkin’s lymphoma (HL). Whole-Body DW-MRI and FDG PET/CT results assessment was done. Comparison between WB-DWI and FDG PET/CT revealed moderate agreement (κ = 0.573) for nodal regions and very good agreement (κ = 0.835) for extra-nodal regions. Finally, individual nodal regions varied from moderate to very good at a kappa value of &gt; 0.69; with the exception of mediastinal hilar nodes which were fair (κ = 0.348).</p> Conclusion <p>WB-DWI demonstrates potential as a radiation-free alternative to PET/CT for staging and treatment response assessment in lymphoma patients. However, larger multicenter studies are still needed to validate WB-DW-MRI's diagnostic performance across diverse lymphoma subtypes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Can whole-body diffusion-weighted magnetic resonance sequence replace 18F-fluorodeoxyglucose-positron emission tomography in the management of lymphoma?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月6日

查看全文
  • Rafik M. Ibrahim,
  • Mwanajaa Abdalla Mwachui,
  • Ahmed El-Gowily,
  • Azza Mohamed Amin Darwish

摘要

Background

Positron emission tomography with 18F-fluorodeoxyglucose (18F-FDG-PET/CT) is the gold standard for staging and treatment response assessment in patients with malignant lymphoma. However, 18F-FDG-PET/CT uses significant dose of ionizing radiation, which is a potential risk of secondary malignancies. Whole-body diffusion-weighted MRI (WB-DW-MRI) is a promising, radiation-free alternative for staging and assessment of response in patients with lymphoma. However, till now, WB-MRI is not routinely used in patients with lymphoma. The aim of this study was to assess the role of whole-body diffusion-weighted MR sequence in management of lymphoma, compared to conventional FDG-PET CT, as well as to ascertain whether WB-DW-MRI is a good alternative to FDG PET/ CT for the diagnosis of lymphoma and subsequent treatment evaluation. The study was conducted on 20 patients (17males, 3 females) who presented with histopathologically proved lymphoma for initial evaluation or for follow-up. All patients were subjected to full history taking, clinical examination report review, as well as other imaging modalities whenever available, followed by FDG PET/CT examination. Patients were then further reevaluated by whole-body diffusion-weighted imaging to determine whether they were comparable in the diagnostic and or treatment response assessment.

Results

Thirty-six of our patients had non-Hodgkin’s lymphoma (NHL), while 4 had Hodgkin’s lymphoma (HL). Whole-Body DW-MRI and FDG PET/CT results assessment was done. Comparison between WB-DWI and FDG PET/CT revealed moderate agreement (κ = 0.573) for nodal regions and very good agreement (κ = 0.835) for extra-nodal regions. Finally, individual nodal regions varied from moderate to very good at a kappa value of > 0.69; with the exception of mediastinal hilar nodes which were fair (κ = 0.348).

Conclusion

WB-DWI demonstrates potential as a radiation-free alternative to PET/CT for staging and treatment response assessment in lymphoma patients. However, larger multicenter studies are still needed to validate WB-DW-MRI's diagnostic performance across diverse lymphoma subtypes.